Kyntra Bio (KYNB) Operating Expenses (2014 - 2026)

Kyntra Bio has disclosed Operating Expenses across 13 years of filings, most recently posting $16.1 million for Q2 2026.

• In Q2 2026, Operating Expenses rose 20.15% year-over-year to $16.1 million; the TTM figure through Jun 2026 stood at $54.9 million (down 38.38% YoY), while the FY2025 annual figure was $52.3 million, down 70.93% from the prior year.
• Operating Expenses came in at $16.1 million for Q2 2026 at Kyntra Bio, down from $17.6 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $132.4 million in Q2 2023 to a low of $6.5 million in Q3 2025.
• Average Operating Expenses over 5 years is $59.9 million, with a median of $47.6 million recorded in 2024.
• The largest YoY upside for Operating Expenses was 44.03% in 2025 against a maximum downside of 86.43% in 2025.
• Over 5 years, Operating Expenses stood at $100.5 million in 2022, then tumbled by 78.82% to $21.3 million in 2023, then sank by 51.77% to $10.3 million in 2024, then jumped by 44.03% to $14.8 million in 2025, then climbed by 8.86% to $16.1 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $16.1 million in Q2 2026, $17.6 million in Q1 2026, and $14.8 million in Q4 2025.